SuperworthRoivant Sciences EPS ROIV
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.39
- Latest quarter, Q1 FY26
- −$0.26
- Fiscal year 2025
- −$0.46
Roivant Sciences' earnings per share was −$0.39 over the twelve months to Jun 30, 2026.
In its latest quarter, Q1 FY26, it was −$0.26.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.46 | n/a |
| FY2024 | −$0.25 | −105% |
| FY2023 | $5.06 | n/a |
| FY2022 | −$1.44 | n/a |
| FY2021 | −$1.25 | n/a |
| FY2020 | −$1.29 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY26 | −$0.26 | n/a | −$0.39 | |
| Q4 FY25 | $0.42 | n/a | −$0.46 | |
| Q3 FY25 | −$0.38 | −265% | −$1.17 | |
| Q2 FY25 | −$0.17 | n/a | −$0.56 | |
| Q1 FY25 | −$0.33 | −375% | −$0.70 | |
| Q4 FY24 | −$0.29 | n/a | −$0.25 | |
| Q3 FY24 | $0.23 | −96% | −$0.15 | |
| Q2 FY24 | −$0.31 | n/a | $5.65 | |
| Q1 FY24 | $0.12 | n/a | $5.56 | |
| Q4 FY23 | −$0.19 | n/a | $5.06 | |
| Q3 FY23 | $6.03 | n/a | $5.20 | |
| Q2 FY23 | −$0.40 | n/a | −$1.32 |
Against its peers
Companies in Biotechnology nearest Roivant Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ROIVRoivant Sciences | −$0.39 | |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| INCYIncyte | $7.85 | +78% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ONCBeOne Medicines | $0.43 | |
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| Peer median | $4.64 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Roivant Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.